Intuitive Surgical reported strong Q4 2024 earnings and positive growth projections
From Nasdaq: 2025-01-23 23:45:11
Intuitive Surgical reported strong financial performance in Q4 2024, with a robust early adoption of their fifth-generation multiport platform, da Vinci 5, leading to healthy procedure growth. The company launched new platforms and focused on increasing adoption of procedures by country. General surgery procedures in the U.S. and regional performance in countries like the U.K., Ireland, Japan, and Germany saw growth. Internationally, benign indications grew faster than cancer indications. Additionally, the company acquired the da Vinci business in Italy, Spain, Portugal, and related territories. Ion and SP procedures showed continued strength and growth in flexible robotics. In 2024, Intuitive Surgical saw a significant increase in system placements, with 271 Ion placements and 96 SP placements, showing growth from the previous year. The company’s systems portfolio, including da Vinci 5, da Vinci Xi, da Vinci X, da Vinci SP, and Ion, along with flexible financing options, helped meet customer needs. System utilization also increased, with multiport, SP, and Ion utilization all showing growth. With revenue reaching $8.4 billion, operating expenses were kept in check, leading to a 29% increase in net income. The launch of da Vinci 5 was successful, with over 2,500 surgeons performing 32,000 procedures using the system in 2024.
Looking ahead to 2025, Intuitive Surgical’s priorities include focusing on the full launch of da Vinci 5, increasing adoption of focused procedures by country, and enhancing industrial scale and product quality. The company also aims to improve the availability of digital tools. In terms of financial performance, Q4 and full-year 2024 revenue, procedures, and system placements met expectations, with a 25% revenue growth in Q4. U.S. procedures saw a 15% increase, while OUS procedures grew by 25%, driven by strong performance in various countries. Overall, the company placed 493 systems in Q4, showing a 19% increase from the previous year. In the fourth quarter of 2024, Intuitive Surgical placed 284 systems in the U.S. and 209 systems outside the U.S., with strong growth in Europe and Asia. Revenue for the quarter was $2.41 billion, a 25% increase over the previous year. Ion procedures increased by 70% year over year, with 69 Ion systems placed in the quarter. Pro forma gross margin improved to 69.5% in the fourth quarter. Operating expenses increased by 9% compared to the previous year, with a $45 million contribution to the Intuitive Foundation. Pro forma net income for the quarter was $805 million, or $2.21 per share. In the fourth quarter of 2024, the company reported a GAAP net income of $686 million, compared to $606 million in the same quarter of 2023. They ended the year with cash and investments of $8.8 billion, planning to expand direct operations in Italy, Spain, and Portugal. Moving forward, they anticipate lower pro forma operating margins in 2025 due to various factors, including higher leasing rates and depreciation expenses, and a shift in product mix. Additionally, the company highlighted the importance of peer-reviewed studies showcasing the benefits of da Vinci robotic-assisted surgery over traditional methods. Innovative technology in robotic-assisted surgery enhances safety and outcomes for patients, benefitting both novice and experienced surgeons. Procedure growth for da Vinci systems in 2024 reached over 2.6 million, with an anticipated 2025 growth of 13% to 16%. Gross profit margin expected to be 67-68% in 2025, impacted by depreciation, product mix, and stronger U.S. dollar. Operating expenses to grow 10-15% in 2025, with noncash stock compensation estimated at $760-790 million. Income tax rate projected to be 22-23% of pre-tax income. U.S. system placements increased by over 35%, indicating potential for more procedures with new capital features. Gross margin in 2025 expected to be lower at 67-68% due to depreciation, product mix, and FX impact. Teams working on cost reductions within this range. Intuitive Surgical aims to reach over 70% gross margin in the midterm with product margin improvements and cost reductions. The company plans a midyear full launch and trade-in cycle for da Vinci 5 versus Xi placements globally. Software updates will enhance analytics, force reflection, ergonomics, and imaging. The impact on placements and trading cycles will be progressive. The capital equipment environment in China remains challenging, impacted by domestic competition and government activities. In the U.S., interest in da Vinci 5 has driven strong placements, while the U.K., Germany, and Japan face mixed dynamics. Intuitive Surgical CEO Gary S. Guthart discusses the company’s R&D investment opportunities, indicating a mix of new technologies, geographic expansions, and additional indications for existing platforms. CFO Jamie E. Samath notes that opex growth of 10-15% will be driven by procedure growth, with tariffs potentially impacting the company due to manufacturing in Mexico. Guthart hints at new digital features for da Vinci 5, emphasizing improved outcomes, enhanced care teams, and potential access to more patients. Analysts express interest in the company’s future strategies and opportunities. In the evolving field of surgical procedures, new categories are emerging to make it easier for surgeons and care teams to reach patients with confidence and speed. Tools and technologies are accelerating learning and building confidence in care teams, benefiting both hospitals and patients. The growth of procedures like Ion and SP is driven by adoption curves and international expansion. Competition is increasing, particularly in China, which could impact selling cycles in the future. Innovation and new capabilities are inspiring the next generation of surgeons and opening doors for future advancements in the field. Intuitive Surgical CEO, Gary Guthart, discusses the company’s strategy to bring additional value to procedures by identifying areas in the surgical ecosystem where they can create value through design and integration. The company focuses on value creation for customers, not just revenue growth. CFO Jamie Samath highlights the potential impact of force feedback instruments and insufflation on revenue per procedure. Analyst Patrick Wood inquires about the margin implications of higher installed base density on servicing existing accounts, with Guthart confirming cost advantages in areas with greater geographic density. Intuitive Surgical believes in improving surgery and acute intervention for better patient outcomes. They focus on the Quintuple Aim: better outcomes, patient experiences, access to care, and lower cost. The company envisions a future with less invasive and better treatments. They value human-centered care and aim to understand patients’ needs. Intuitive Surgical appreciates support on their journey and looks forward to future discussions. The recent earnings call included key participants such as the CEO, CFO, and analysts discussing the company’s performance and future outlook. The Motley Fool provided a transcript of the call, with a disclaimer on potential errors or inaccuracies. The Motley Fool discloses its positions in Intuitive Surgical.
Read more at Nasdaq: Intuitive Surgical (ISRG) Q4 2024 Earnings Call Transcript